CAPR — Capricor Therapeutics, Inc.

Summary of Capricor Therapeutics Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of September 30, 2025, Capricor reported cash, cash equivalents, and marketable securities totaling approximately $98.6 million, sufficient to cover anticipated expenses into 2026.
• Revenue: Revenue for Q3 2025 was $0, compared to $2.3 million for Q3 2024. The decline is attributed to the completion of revenue recognition from a prior distribution agreement.
• Operating Expenses:
  • R&D expenses increased to $18.1 million in Q3 2025 from $11 million in Q3 2024.
  • General and administrative (G&A) expenses rose to $4.1 million from $2.2 million in Q3 2024.
• Net Loss: The net loss for Q3 2025 was approximately $24.6 million, compared to $12.6 million in Q3 2024.

2. Strategic Updates and Business Highlights

• HOPE-3 Phase 3 Study: Capricor is nearing a major milestone with the upcoming top-line readout from the HOPE-3 study of Daramycin for Duchenne muscular dystrophy (DMD). The study enrolled 105 participants and aims to provide critical efficacy data, particularly for non-ambulant patients.
• Manufacturing Readiness: The San Diego facility is fully operational and has passed FDA inspections, addressing prior CMC (Chemistry, Manufacturing, and Controls) concerns.
• Regulatory Strategy: Following a Complete Response Letter (CRL) from the FDA in July, Capricor plans to submit HOPE-3 results as a complete response to the CRL, with a focus on left ventricular ejection fraction (LVEF) as a key secondary endpoint.

3. Forward Guidance and Outlook

• Capricor aims for FDA approval of Daramycin in 2026, with a focus on addressing cardiomyopathy associated with DMD. They are also eligible for an $80 million milestone payment from NS Pharma upon approval.
• The company is preparing for potential commercialization, including physician education and market access strategies.
• Initial data from the HOPE-3 study is expected within weeks, which will be pivotal for the company's future.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: The absence of revenue in 2025 compared to the previous year raises concerns about financial sustainability.
• Increased Losses: The net loss has more than doubled year-over-year, indicating rising operational costs and the need for effective cost management.
• Regulatory Risks: The FDA's stringent review process and the potential for a Type 2 classification for the resubmission may extend the timeline for approval and commercialization.
• Market Pressures: The evolving landscape of pricing policies and competition in the DMD treatment space could pose challenges.

5. Notable Q&A Insights

• Data Release Expectations: CEO Linda Marbán confirmed that the top-line data will include primary and key secondary endpoints, with a detailed conference call to follow the data release.
• Statistical Analysis Plan (SAP): The SAP is designed to analyze both primary (performance of upper limb) and secondary (LVEF) endpoints, with flexibility from the FDA to consider the totality of data.
• Cohort Analysis: The analysis will focus on Cohort B, which is manufactured at the commercial facility, to ensure regulatory confidence in the product's efficacy.
• Regulatory Flexibility: The FDA has indicated a willingness to consider the overall data, even if the primary endpoint is not met, particularly if significant results are seen in cardiac function.

This earnings call reflects Capricor's critical juncture as it approaches significant clinical milestones while navigating financial and regulatory challenges.